Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
06 Fevereiro 2025 - 9:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 6, 2025
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F
Trading
in Novo Nordisk shares by board members, executives and associated persons
Bagsværd,
Denmark, 6 February 2025 — This company announcement discloses the data of the
transaction(s) made in Novo Nordisk shares by the company’s board members, executives and
their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market
abuse.
The
company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo
Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and
their associated persons.
Please
find below a statement of such trading in shares issued by Novo Nordisk.
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Liselotte
Sofie Hyveled |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Member
of the Board of Directors |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
1,407
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
1,407
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
98,702
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
98,702
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| 618.10
DKK |
32
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
32 shares
19,779
DKK |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
AQUIS
EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB) |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| 619.48
DKK |
1,104
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
1,104
shares
683,905
DKK |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
AQUIS
EXCHANGE EUROPE |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| 617.56
DKK |
978
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
978
shares
603,976
DKK |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
CBOE
EUROPE - DXE PERIODIC (NL) |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| 621.01
DKK |
42
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
42 shares
26,083
DKK |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
CBOE
EUROPE - DXE DARK ORDER BOOK (NL) |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| 618.17
DKK |
8,331
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
8,331
shares
5,149,984
DKK |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
CBOE
EUROPE - DXE ORDER BOOKS (NL) |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| 618.14
DKK |
1,577
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
1,577
shares
974,805
DKK |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
TURQUOISE
EUROPE |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Lars
Fruergaard Jørgensen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
President
and CEO |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| 618.88
DKK |
22,936
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
22,936
shares
14,194,575
DKK |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
NASDAQ
COPENHAGEN A/S |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Maziar
Mike Doustdar |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
36,956
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
36,956
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Maziar
Mike Doustdar |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
614.55 |
1,852
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
1,852
shares
DKK
1,138,154 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Nasdaq
Copenhagen |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Ludovic
Helfgott |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
27,765
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
27,765
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Ludovic
Helfgott |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
614.55 |
8,990
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
8,990
shares
DKK
5,524,840 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Nasdaq
Copenhagen |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Ludovic
Helfgott |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
617.00 |
12,000
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
12,000
shares
DKK
7,404,000 |
| e) |
Date
of the transaction |
2025-02-06 |
| f) |
Place
of the transaction |
Nasdaq
Copenhagen |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Karsten
Munk Knudsen |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
30,728
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
30,728
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Martin
Holst Lange |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
30,728
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
30,728
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Tania
Sabroe |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
10,561
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
10,561
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Marcus
Schindler |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
30,728
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
30,728
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Camilla
Sylvest |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
30,728
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
30,728
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Camilla
Sylvest |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Sale
of shares |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
615.00 |
15,364
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
15.364
shares
DKK
9,448,860 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Nasdaq
Copenhagen |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
| 1 |
Details
of the person discharging managerial responsibilities/person closely associated |
| a) |
Name
of the Board member/Executive/Associated Person |
Henrik
Ehlers Wulff |
| 2 |
Reason
for the notification |
| a) |
Position/status |
Executive
Vice President |
| b) |
Initial
notification/Amendment |
Initial
notification |
| 3 |
Details
of the issuer |
| a) |
Name |
Novo
Nordisk A/S |
| b) |
LEI |
549300DAQ1CVT6CXN342 |
| 4 |
Details
of the transaction(s) |
| a) |
Description
of the financial instrument,
type
of instrument, |
Shares |
|
|
| Identification
code |
Novo
Nordisk B DK0062498333 |
|
| b) |
Nature
of the transaction |
Other
transaction (transfer of shares in
accordance
with Long Term Incentive programme) |
| c) |
Price(s)
and volume(s) |
|
| |
Price(s) |
Volume(s) |
|
| DKK
0.00 |
32,448
shares |
| |
|
| |
| d) |
Aggregated
information
·
Aggregated volume
·
Price |
32,448
shares
DKK
0.00 |
| e) |
Date
of the transaction |
2025-02-05 |
| f) |
Place
of the transaction |
Outside
a trading venue |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
Novo
Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts
for further information
| Media: |
|
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
| |
|
| Investors: |
|
|
Jacob Martin Wiborg
Rode
+45 3075 5956
jrde@novonordisk.com |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
| |
|
|
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com |
| |
|
|
Max Ung
+45 3077 6414
mxun@novonordisk.com
|
Frederik Taylor
Pitter
+1 609 613 0568
fptr@novonordisk.com |
|
Novo Nordisk A/S
Investor Relations |
Novo Allé 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
| |
|
|
Company announcement No 8 / 2025 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 6, 2025 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (NYSE:NVO)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Novo Nordisk (NYSE:NVO)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
